| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Newhall Charles W III is a Director at SUPN. Recent filings cover 0 purchases and 7 sales. Those positions are worth an estimated $1.6M at current prices.
Our model assigns Newhall Charles W III a below-average insider score of 34/100, based on 6 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -26.8%.
Newhall Charles W III's largest disclosed position is in SUPN as Director, worth about $1.6M. The recent filings there lean toward selling, a net 44,200 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Director | Sell | 25,000 | $50.77 | $1,269,234.00 | -19.3% | +3.5% | - | |
| Aug 27, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Director | Sell | 3,588 | $45.01 | $161,495.88 | -2.7% | +2.2% | - | |
| Aug 25, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Director | Sell | 1,000 | $45.00 | $45,000.00 | -0.7% | +1.6% | - | |
| Aug 22, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Director | Sell | 1,412 | $45.00 | $63,540.00 | -1.0% | -0.2% | - | |
| Nov 11, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Director | Sale+OE | 10,700 | $36.24 | $387,768.00 | -7.6% | +3.6% | +25.9% | |
| Nov 16, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Director | Sale+OE | 2,500 | $28.01 | $70,025.00 | -2.1% | -1.1% | +27.6% |